Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Elsita Jungkurth"'
Autor:
Brian Shine, Robert Pell, Weiyu Ye, Mark R Middleton, Tim James, Stephanie Jones, Robert A Watson, Ian S D Roberts, Monika Hofer, Damian Jenkins, Miranda J Payne, Nicholas Coupe, Chelsea A Taylor, Elsita Jungkurth, Rosalin Cooper, Orion Tong, Eleni Ieremia, David Maldonado-Perez, Benjamin P Fairfax
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 4 (2024)
We describe three cases of critical acute myositis with myocarditis occurring within 22 days of each other at a single institution, all within 1 month of receiving the initial cycle of the anti-PD-1 drug pembrolizumab. Analysis of T cell receptor rep
Externí odkaz:
https://doaj.org/article/97a4f9e90ef947358cb17f5b1cd03194
Autor:
Robert A. Watson, Chelsea A. Taylor, Orion Tong, Rosalin Cooper, Elsita Jungkurth, Piyush Kumar Sharma, Bethan Storey, Weiyu Ye, Bo Sun, Alba Verge de los Aires, Flavia Matos Santo, Isar Nassiri, James J. Gilchrist, Eleni Ieremia, Mark R. Middleton, Benjamin P. Fairfax
Immune checkpoint blockade (ICB) has markedly improved outcomes across a range of tumours, including metastatic melanoma (MM). However, peripheral biomarkers of response remain lacking and underlying mechanisms of action incompletely described. A num
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bb06cfffc46000bf093ea5dec1de454e
https://doi.org/10.1101/2023.02.11.528080
https://doi.org/10.1101/2023.02.11.528080
Autor:
Benjamin Fairfax, Chelsea Taylor, Robert Watson, Orion Tong, Weiyu Ye, Isar Nassiri, James Gilchrist, Alba Verge de los Aires, Piyush Sharma, Surya Koturan, Rosalin Cooper, Victoria Woodcock, Elsita Jungkurth, Brian Shine, Nicholas Coupe, Miranda Payne, Vivek Naranbhai, Stefan Groha, Paul Emery, Kulveer Mankia, Matthew Freedman, Toni Choueiri, M Middleton, Alexander Gusev
Although treatment with immune checkpoint blockade (ICB) has transformed outcomes for patients with melanoma (1, 2), it frequently triggers immune related adverse events (irAEs), causing serious morbidity and presenting a major hurdle to immuno-oncol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::860696c0efeb58e147c6b78c5707d2a0
https://doi.org/10.21203/rs.3.rs-1531341/v1
https://doi.org/10.21203/rs.3.rs-1531341/v1
Autor:
Chelsea A. Taylor, Robert A. Watson, Orion Tong, Weiyu Ye, Isar Nassiri, James J. Gilchrist, Alba Verge de los Aires, Piyush Kumar Sharma, Surya Koturan, Rosalin A. Cooper, Victoria K. Woodcock, Elsita Jungkurth, Brian Shine, Nicholas Coupe, Miranda J. Payne, David N. Church, Vivek Naranbhai, Stefan Groha, Paul Emery, Kulveer Mankia, Matthew L. Freedman, Toni K. Choueiri, Mark R. Middleton, Alexander Gusev, Benjamin P. Fairfax
Publikováno v:
Nature medicine. 28(12)
Treatment with immune checkpoint blockade (ICB) frequently triggers immune-related adverse events (irAEs), causing considerable morbidity. In 214 patients receiving ICB for melanoma, we observed increased severe irAE risk in minor allele carriers of
Publikováno v:
Journal of Genetic Counseling
As population‐level carrier screening panels for reprogenetic information emerge globally, conditions to be included, and the timing of implementation is widely debated. Thalassemia is the only condition for which population‐based prenatal carrie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d031730267a937389fc0239d0c56f50
http://wrap.warwick.ac.uk/132956/31/WRAP-social-cultural-influences-genetic-screening-programme-acceptability-Boardman-2020.pdf
http://wrap.warwick.ac.uk/132956/31/WRAP-social-cultural-influences-genetic-screening-programme-acceptability-Boardman-2020.pdf